To the full analysis
Ono Pharmaceutical stock: growth
4528.TOno Pharmaceutical reported $3.23B in revenue for fiscal 2026, up 5.9% on the prior year, up 10.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
7%
per year from 2007 to 2026, per share 8.3%
Earnings (Annual rate)
3.7%
per year from 2007 to 2026, per share 4.8%
Free cash flow (Annual rate)
6.8%
per year from 2007 to 2026, per share 8%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 10.8% | 12.4% | 7.0% |
| Revenue per share | 12.1% | 13.8% | 8.3% |
| Earnings | −1.5% | 10.8% | 3.7% |
| Earnings per share | −0.3% | 12.2% | 4.8% |
| Free cash flow | 14.3% | 36.5% | 6.8% |
| Free cash flow per share | 15.7% | 38.2% | 8.0% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $887.38M | $220.86M | $235.11M |
| 2008 | $913.59M | $219.45M | $218.72M |
| 2009 | $855.1M | $148.82M | $144.13M |
| 2010 | $851.53M | $174.57M | $113.28M |
| 2011 | $846.95M | $151.67M | $178.48M |
| 2012 | $912.84M | $152.54M | $122.8M |
| 2013 | $894.23M | $143.52M | $86.21M |
| 2014 | $896.99M | $127.39M | $141.56M |
| 2015 | $850.21M | $81.25M | $87.91M |
| 2016 | $1B | $156.42M | $36.45M |
| 2017 | $1.53B | $349.37M | $373.49M |
| 2018 | $1.64B | $314.87M | $670.02K |
| 2019 | $1.81B | $322.73M | $278.47M |
| 2020 | $1.83B | $373.86M | $417.55M |
| 2021 | $1.94B | $472.3M | $419.29M |
| 2022 | $2.26B | $504.19M | $352.74M |
| 2023 | $2.8B | $705.86M | $966.02M |
| 2024 | $3.15B | $801.38M | $667.77M |
| 2025 | $3.05B | $313.39M | $482.34M |
| 2026 | $3.23B | $436.87M | $819.03M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 13 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ¥159.70)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 27 Mar 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.